1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 20 APRIL 2015

Cancer Drug News 20 APRIL 2015

  • April 2015
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - Argos/Lummy Deal Indicative Of Shift Towards Innovation Within Sino-foreign Partnerships
Industry Trend Analysis - Positive Ibrance Data Set Pfizer Further Ahead Although Competition Will Arrive Soon
Industry Brief - Genmab Earns Fifth Milestone In Daratumumab Collaboration with Janssen
Industry Trend Analysis - Expansion Of Copanlisib Programme Highlights Changes Within Bayer And The NHL Market
Industry Brief - FDA Accepts NDA Filing For Bendamustine Rapid Infusion
Industry Brief - Panther Licenses TDZD-8 From University Of Rochester For Leukaemia
Industry Brief - Merck KGaA/Pfizer Initiate Avelumab Phase III Study In Stage IIIb/IV NSCLC
Industry Brief - FDA Grants ODD To AstraZeneca's Tremelimumab For Malignant Mesothelioma
Industry Brief - Opdivo Phase III LC Trial Stopped Early Following Favourable OS Results
Industry Trend Analysis - Keytruda's Impending Approval Will Cause BMS' NSCLC Advantage To Slip
Industry Brief - Health Canada Approves New Indication For Xtandi In MCRPCA
Industry Brief - Active Biotech/Ipsen Discontinue Tasquinimod Development In PCA
Industry Brief - MHRA Approves New Indication For Somatuline Autogel
Industry Brief - 4SC/Menarini Sign Resminostat Licensing Deal In Asia-Pacific
Industry Brief - Transgene/FDA Reach SPA Agreement On Pexa-Vec Phase III Trial
Industry Brief - FDA Grants ODD To Oncolytics' Reolysin For Malignant Glioma
Industry Brief - RXi's Samcyprone Gains FDA ODD For Late-Stage Malignant Melanoma
Industry Brief - Provectus Begins PV-10 Phase III Comparative Trial For Melanoma
Industry Brief - AstraZeneca's Selumetinib Gains FDA ODD For Uveal Melanoma
Industry Brief - TetraLogic/Merck Collaborate On Keytruda/Birinapant Combination Phase I Trial In Solid Tumours
Industry Brief - Ventana/Astellas To Co-Develop Tissue Diagnostics For Targeted Cancer Therapies
Industry Brief - Immunocore/MedImmune Enter Second Collaboration
Industry Brief - US Patent Allowance Granted Covering PV-10 For Cancer
Industry Brief - Sanofi To Apply Innate's Site-Specific Conjugation Technology To Develop ADCs
Industry Trend Analysis - Roche's Pipeline Will Benefit From Genomic Diagnostic Acquisition
Industry Brief - TVM Life Science Ventures VII Invests In Esperas Pharma
Industry Trend Analysis - J&J Oncology Segment Gaining Momentum
Industry Brief - Innocrin Raises Funds To Accelerate VT-464 Development In CRPCA

Table Of Contents

Cancer Drug News 20 APRIL 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer and Breast Cancer Statistics in Switzerland

  • February 2017
    138 pages
  • Cancer  

    Breast Cancer  

    Obesity  

  • Switzerland  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Cancer Statistics

6 days ago

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.